Identification of New Biomarkers of Insulin Resistance

Diabetes Mellitus, Type 2 Clinical Trial

Official title:

Identification of New Biomarkers of Insulin Resistance

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03362554
• Other study ID #: RC-FH1158
• Status: Active, not recruiting
• Phase: N/A
• Start date: February 1, 2018
• Est. completion date: January 2028

Study information

• Verified date: November 2023
• Source: University of Bath
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Diabetes is a chronic metabolic disease affecting 415 million people worldwide, 90% of cases are type 2 which is frequently associated with obesity and a sedentary lifestyle. In healthy individuals, insulin stimulates increased cell surface expression of a glucose transporter (GLUT4) in muscle and fat tissue. This prevents blood sugar levels becoming dangerously high by taking sugar into the muscle and fat cells. Loss of this response ('insulin resistance') frequently occurs before the development of type 2 diabetes. Understanding the cell biology of insulin resistance is necessary to develop more effective treatments for this condition and prevent further cases of type 2 diabetes. Previous work showed that this movement of GLUT4 is dependent on a small protein called Rab3 which is downregulated in insulin resistance. Rab3 protein levels are also sensitive to inflammation, a state that is exacerbated by obesity. In order to examine whether Rab3 is an early biomarker of insulin resistance, we aim to measure the levels of this protein and its interactors in fat and muscle samples from insulin resistant individuals. It has been shown that insulin sensitivity can be improved with an intervention as short as three weeks when net energy intake is sufficiently reduced. Therefore, by taking the same measurements before and after this three week intervention we can observe any improvements in Rab3 expression and insulin sensitivity at a cellular level. There is also evidence for an effect of the gut microbiome on insulin sensitivity so we will measure any changes that take place in the gut microbiome following this intervention, which can be determined from faecal samples taken before and after the three weeks.

Description:

Diabetes is a chronic metabolic disease affecting 415 million people worldwide and 3.5 million people in the UK, with ninety percent suffering from type 2 diabetes. Type 2 diabetes is characterised by the inability of muscle and fat tissues to adequately respond to physiological levels of insulin (peripheral tissue insulin resistance), and to restore the normal levels of sugars in the bloodstream. Insulin resistance may occur prior to the development of type 2 diabetes and has been shown to be strongly linked to lifestyle and to obesity, although the underlying mechanisms are incompletely resolved. A defining characteristic of insulin resistance is abnormal glucose transport as a result of decreased cell surface expression of the glucose receptor GLUT4. In healthy adipose and skeletal muscle this receptor is trafficked to the cell surface in response to an insulin stimulus. We have shown that this translocation to the cell membrane requires the protein Rab3, and expression levels of this protein are reduced in cell models of insulin resistance. We hypothesise that this downregulation of Rab3 is associated with the development of insulin resistance and its activity would increase following the restoration of insulin sensitivity. The primary aim of this study is to examine the effect on Rab3 levels and GLUT4 trafficking of a diet and exercise intervention that has been previously shown to increase insulin sensitivity. Additionally, the gut microbiome will be studied before and after the intervention to determine any relationship to insulin sensitivity. Recent evidence suggests the microbiome has a significant role in the development of insulin resistance through a number of potential mechanisms. Infusion of microbiota from lean donors has been shown to result in improved insulin sensitivity in male recipients with metabolic syndrome, with concomitant increases in the prevalence of butyrate-producing intestinal microbiota. Exercise is associated with greater microbial diversity, including increases in butyrate-producing microbes. No study to date has monitored insulin sensitivity and microbiota composition before and after an exercise and diet intervention, and so this will lead to a better understanding of the mechanisms that lead to insulin resistance and subsequently type 2 diabetes. The study participants will include males and females aged between 40-65 years who fit the criteria for inclusion. After monitoring of normal daily activities for 7 days, volunteers will reduce their calorie intake by 5000 kcal/week and take part in 5 weekly exercise sessions for 3 weeks. Participants will attend one session of laboratory testing before and one after this period which will take place at the University of Bath. This intervention should be sufficient to improve insulin sensitivity and allow us to study the cellular changes that will have taken place during this time.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 30
• Est. completion date: January 2028
• Est. primary completion date: January 31, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 40 Years to 65 Years

Eligibility

Inclusion Criteria:

• Male or female
• Age 40-65
• BMI =25 to = 40 kg/m2
• Physical activity level <1.75 (daily average)
• Waist size >80 cm (female) or >94 cm (male)
• Weight stable for >3 months

Exclusion Criteria:

• Inability to undertake exercise as determined by PAR-Q
• Diagnosed diabetes
• Ongoing or planned lifestyle changes (diet/exercise)
• Recent large shift in bodyweight (>2.5%) within the last 3 months?
• Smoker (or having ceased <6mo ago)
• Metabolic disorders
• Hypertension defined as >160/100
• Use of anti-inflammatory medication: NSAIDs
• Cardiovascular disease
• Any bleeding disorder or taking anticoagulant medication
• Use of antibiotics within the last three months
• Use of pro/pre-biotics within one month of first trial day.

Related Conditions & MeSH terms

• Diabetes Mellitus, Type 2
• Gastrointestinal Microbiome
• Inflammation
• Insulin Resistance

Intervention

Behavioral:
• Controlled diet and exercise.
The intervention will involve 3 weeks of a diet and exercise program designed to cause a net energy decrease of 7000 kcal/week compared to habitual behaviour. This will be achieved through: Five exercise sessions per week at 70% VO2 max, using 400 kcal per session. Reduction of their standard diet by 5000 kcal per week Before and after this intervention period participants will take part in a trial day which includes measurement of body composition (using DEXA) and blood sugar control (oral glucose tolerance test). Samples of blood, adipose, skeletal muscle and faeces will also be taken.

Locations

Country	Name	City	State
United Kingdom	Department for Health, University of Bath	Bath

Sponsors (2)

Lead Sponsor	Collaborator
University of Bath	Teagasc

Country where clinical trial is conducted

United Kingdom, 

References & Publications (7)

Campbell SC, Wisniewski PJ 2nd. Exercise is a Novel Promoter of Intestinal Health and Microbial Diversity. Exerc Sport Sci Rev. 2017 Jan;45(1):41-47. doi: 10.1249/JES.0000000000000096. — View Citation

DiabetesUK, Facts and Stats. 2016: https://diabetes-resources-production.s3-eu-west-1.amazonaws.com/diabetes-storage/migration/pdf/DiabetesUK_Facts_Stats_Oct16.pdf.

Kahn BB, Flier JS. Obesity and insulin resistance. J Clin Invest. 2000 Aug;106(4):473-81. doi: 10.1172/JCI10842. No abstract available. — View Citation

Koumanov F, Pereira VJ, Richardson JD, Sargent SL, Fazakerley DJ, Holman GD. Insulin regulates Rab3-Noc2 complex dissociation to promote GLUT4 translocation in rat adipocytes. Diabetologia. 2015 Aug;58(8):1877-86. doi: 10.1007/s00125-015-3627-3. Epub 2015 May 30. — View Citation

Utzschneider KM, Kratz M, Damman CJ, Hullar M. Mechanisms Linking the Gut Microbiome and Glucose Metabolism. J Clin Endocrinol Metab. 2016 Apr;101(4):1445-54. doi: 10.1210/jc.2015-4251. Epub 2016 Mar 3. Erratum In: J Clin Endocrinol Metab. 2016 Jun;101(6):2622. — View Citation

Vrieze A, Van Nood E, Holleman F, Salojarvi J, Kootte RS, Bartelsman JF, Dallinga-Thie GM, Ackermans MT, Serlie MJ, Oozeer R, Derrien M, Druesne A, Van Hylckama Vlieg JE, Bloks VW, Groen AK, Heilig HG, Zoetendal EG, Stroes ES, de Vos WM, Hoekstra JB, Nieuwdorp M. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology. 2012 Oct;143(4):913-6.e7. doi: 10.1053/j.gastro.2012.06.031. Epub 2012 Jun 20. Erratum In: Gastroenterology. 2013 Jan;144(1):250. — View Citation

Walhin JP, Dixon NC, Betts JA, Thompson D. The impact of exercise intensity on whole body and adipose tissue metabolism during energy restriction in sedentary overweight men and postmenopausal women. Physiol Rep. 2016 Dec;4(24):e13026. doi: 10.14814/phy2.13026. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in insulin sensitivity	Response to oral glucose tolerance test	120 min (change after 3 weeks)
Secondary	Rab3 protein expression	Levels of Rab3 in adipose and muscle samples	Change after 3 weeks
Secondary	GLUT4 pathway protein expression	Expression levels of GLUT4 pathway proteins in adipose and muscle samples	Change after 3 weeks
Secondary	Metabolic markers	Levels of circulating metabolic markers implicated in insulin resistance	Change after 3 weeks
Secondary	Inflammatory markers	Levels of circulating inflammatory cytokines	Change after 3 weeks
Secondary	Gut microbiome	Species of microorganisms present in fecal samples	Change after 3 weeks
Secondary	Body composition	Assessed by whole body DEXA scan	Change after 3 weeks
Secondary	Waist circumference		Change after 3 weeks
Secondary	Body mass		Change after 3 weeks